Background: Nowadays, combination therapy with peginteferon plus ribavirin is the standard treatment for chronic hepatitis C. This scheme achieves, according to randomized and controlled trials, viral eradication in 54% to 56% of treated patients (42% to 46% of patients infected with genotype 1 and 76% to 82% of those with genotypes 2 or 3).
Objective: To evaluate the effectiveness of combined treatment with peginteferon alpha 2a and ribavirin for chronic hepatitis C, in daily clinical practice.
Patients And Methods: All patients with chronic hepatitis C who were treated by the authors with combined treatment (peginteeferon alpha 2a plus ribavirin), from January 2001 to July 2008, were included. Patients who completed the treatment as well as those that ended it earlier were included in the analysis.
Results: In this retrospective and multicentric study 75 patients with chronic hepatitis C treated with peginterferon alpha 2a plus ribavirin were enrolled (male gender represented 60%, average age was 42.3 years, genotype 1 meant 58.6% and 31.5% of patients had cirrhosis). The global sustained virological response, according to intention-to-treat analysis, was observed in 37 patients (49%).
Conclusions: The global results in daily clinical practice showed a viral eradication rate close to that published by controlled and randomized studies.
Download full-text PDF |
Source |
---|
Aliment Pharmacol Ther
December 2024
Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Paris, France.
Background: Conflicting results have been reported on the impact of tenofovir versus entecavir on liver-related outcomes.
Aims: To explore trends in clinical outcomes in chronic hepatitis B virus (HBV)-infected patients and compare the impact of tenofovir versus entecavir on the risk of hepatocellular carcinoma (HCC), liver transplantation (LT) and mortality.
Methods: We used the French National Health Insurance Databases (SNDS) to identify HBV-infected patients.
Gastroenterol Rep (Oxf)
December 2024
Department of Laboratory Medicine, First Hospital of Jilin University, Changchun, Jilin, P. R. China.
Hepatic fibrosis, a degenerative liver lesion, significantly contributes to the deterioration and mortality among patients with chronic liver diseases. The condition arises from various factors including toxins, such as alcohol, infections like different types of viral hepatitis, and metabolic diseases. Currently, there are no effective treatments available for liver fibrosis.
View Article and Find Full Text PDFArch Razi Inst
June 2024
Department of Pharmacy Practice, P.E.S. College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Hepatic encephalopathy (HE) is a clinical syndrome that can result from acute and chronic liver disorders, such as hepatitis, liver failure caused by alcohol or drugs, autoimmune diseases, metabolic diseases, cirrhosis, different types of tumors, and infections. This study aimed to investigate the effects of different doses of Beta-myrcene (β-myrcene) on the improvement of HE caused by thioacetamide (TAC) in male rats. To induce liver failure and acute damage in the studied animals, TAC was administered to rats at a dose of 100 mg/kg of body weight through an intraperitoneal (IP) injection with 24-hour intervals for seven consecutive days.
View Article and Find Full Text PDFNoncoding RNA Res
April 2025
Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.
MicroRNAs (miRNAs) are classified as small, non-coding RNAs that play crucial roles in diverse biological processes, including cellular development, differentiation, growth, and metabolism. MiRNAs regulate gene expression by recognizing complementary sequences within messenger RNA (mRNA) molecules. Recent studies have revealed that miR-145-5p functions as a tumor suppressor in several cancers, including lung, liver, and breast cancers.
View Article and Find Full Text PDFBMC Med
December 2024
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing, 100191, China.
Background: Risk prediction models can identify individuals at high risk of chronic liver disease (CLD), but there is limited evidence on the performance of various models in diverse populations. We aimed to systematically review CLD prediction models, meta-analyze their performance, and externally validate them in 0.5 million Chinese adults in the China Kadoorie Biobank (CKB).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!